SCHEMBL5023683

SCHEMBL5023683

CCOc1ccccc1C(=O)c1oc2ccc(Cl)cc2c1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.50
TP53 P04637 2/20 0.50
TSHR P16473 2/20 0.50
MEN1 O00255 1/20 0.50
USP2 O75604 1/20 0.50
GAA P10253 1/20 0.50
ALOX15 P16050 1/20 0.50
MAPK1 P28482 1/20 0.50
KMT2A Q03164 1/20 0.50
KCNMA1 Q12791 1/20 0.50
MGAM O43451 1/20 0.48
KDM4E B2RXH2 2/20 0.44
MCL1 Q07820 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 2/20 0.43
RAB9A P51151 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MAOB P27338 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5023109 0.88 KDM4E (0.55) MAPTTP53TSHRMEN1USP2
SCHEMBL14364718 0.86 MAPT (0.43) MAPTTP53GAAMAPK1KMT2A
SCHEMBL14277067 0.78 KDM4E (0.52) MAPTMEN1KMT2AKDM4EMCL1
SCHEMBL758464 0.75 KDM4E (0.67) MAPTTP53MAPK1KDM4EMCL1
SCHEMBL5026875 0.75 KDM4E (0.51) MAPTKMT2AKDM4EMCL1SMN1; SMN2
SCHEMBL6061022 0.73 KDM4E (0.47) MAPTKMT2AKDM4EMCL1SMN1; SMN2
SCHEMBL6953541 0.73 RECQL (0.60) MAPTTP53TSHRMEN1USP2
SCHEMBL5067315 0.71 NPC1 (0.52) MAPTTP53MEN1MAPK1KMT2A
SCHEMBL5736871 0.71 KDM4E (0.72) MAPTTP53TSHRMEN1MAPK1
SCHEMBL206583 0.71 HCRTR1 (0.66) MAPTTSHRMEN1GAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8486996-B2 Aroylfuranes and aroylthiophenes BASILEA PHARMACEUTICA AG (CH) 2013-07-16 US disclosed
US-8486996-B2 Aroylfuranes and aroylthiophenes BASILEA PHARMACEUTICA AG (CH) 2013-07-16 US disclosed
US-8486996-B2 Aroylfuranes and aroylthiophenes BASILEA PHARMACEUTICA AG (CH) 2013-07-16 US disclosed
EP-1894917-A1 Aryloxy- and arylthioxyacetophenone-type compounds for the treatment of cancer Basilea Pharmaceutica AG (CH) 2008-03-05 EP disclosed
EP-1894917-A1 Aryloxy- and arylthioxyacetophenone-type compounds for the treatment of cancer Basilea Pharmaceutica AG (CH) 2008-03-05 EP disclosed
EP-1697336-B1 AROYLFURANES AND AROYLTHIOPHENES SUITABLE FOR THE TREATMENT OF CANCER BASILEA PHARMACEUTICA AG (CH) 2007-12-19 EP disclosed
US-20060205739-A1 Aroylfuranes and aroylthiophenes BASILEA PHARMACEUTICA AG 2006-09-14 US disclosed
EP-1697336-A2 AROYLFURANES AND AROYLTHIOPHENES SUITABLE FOR THE TREATMENT OF CANCER Basilea Pharmaceutica AG (CH) 2006-09-06 EP disclosed
WO-2005061476-A2 AROYLFURANES AND AROYLTHIOPHENES BASILEA PHARMACEUTICA AG (CH) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205739-A1 Aroylfuranes and aroylthiophenes TPMT, APRT, ABAT MAPT 1505/4885TP53 401/4885TSHR 1612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.